サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1293819

HPV関連疾患市場：適応症別（AIN、肛門がん、子宮頸がん）、治療法別（予防、治療）、流通別-2023～2030年の世界予測

HPV Associated Disorders Market by Indication (AIN, Anal Cancer, Cervical Cancer), Therapy (Prevention, Treatment), Distribution - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
HPV関連疾患市場：適応症別（AIN、肛門がん、子宮頸がん）、治療法別（予防、治療）、流通別-2023～2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

HPV関連疾患の世界市場は大きく成長すると予測され、2023年には93億382万米ドル、CAGRは6.07%と予測され、2030年には驚異的な141億1,219万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のHPV関連疾患市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.HPV関連疾患の世界市場規模および予測は？

2.予測期間中、世界のHPV関連疾患市場を形成するCOVID-19の阻害要因と影響は？

3.HPV関連疾患の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.HPV関連疾患の世界市場における競争戦略は？

5.HPV関連疾患の世界市場における技術動向と規制の枠組みは？

6.HPV関連疾患の世界市場における主要ベンダーの市場シェアは？

7.HPV関連疾患の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • HPV関連疾患の有病率の上昇
      • 標的療法の成長と発展
      • HPV障害に対する政府の積極的な支援と取り組み
    • 抑制要因
      • HPVに関連する副作用
    • 機会
      • がん調査への資金と投資の増加
      • HPV共同検査における技術進歩の進展
    • 課題
      • いくつかの治療選択肢に関する患者の認識の欠如
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 HPV関連疾患市場：適応症別

  • イントロダクション
  • AIN
  • 肛門がん
  • 子宮頸がん
  • CIN
  • 性器いぼ

第7章 HPV関連疾患市場：治療法別

  • イントロダクション
  • 予防
  • 治療

第8章 HPV関連疾患市場：流通別

  • イントロダクション
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 南北アメリカのHPV関連疾患市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のHPV関連疾患市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのHPV関連疾患市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HPV ASSOCIATED DISORDERS MARKET RESEARCH PROCESS
  • FIGURE 2. HPV ASSOCIATED DISORDERS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 5. HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
  • FIGURE 6. HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 7. HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. HPV ASSOCIATED DISORDERS MARKET DYNAMICS
  • FIGURE 9. HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. HPV ASSOCIATED DISORDERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 5. HPV ASSOCIATED DISORDERS MARKET SIZE, BY AIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. HPV ASSOCIATED DISORDERS MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HPV ASSOCIATED DISORDERS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HPV ASSOCIATED DISORDERS MARKET SIZE, BY CIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HPV ASSOCIATED DISORDERS MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 11. HPV ASSOCIATED DISORDERS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HPV ASSOCIATED DISORDERS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 14. HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HPV ASSOCIATED DISORDERS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. HPV ASSOCIATED DISORDERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 145. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 146. HPV ASSOCIATED DISORDERS MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E9189

The Global HPV Associated Disorders Market is forecasted to grow significantly, with a projected USD 9,303.82 million in 2023 at a CAGR of 6.07% and expected to reach a staggering USD 14,112.19 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global HPV Associated Disorders Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global HPV Associated Disorders Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Indication, market is studied across AIN, Anal Cancer, Cervical Cancer, CIN, and Genital Warts. The AIN is projected to witness significant market share during forecast period.

Based on Therapy, market is studied across Prevention and Treatment. The Treatment is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.00% in 2022, followed by Asia-Pacific.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global HPV Associated Disorders Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global HPV Associated Disorders Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global HPV Associated Disorders Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global HPV Associated Disorders Market?

4. What is the competitive strategic window for opportunities in the Global HPV Associated Disorders Market?

5. What are the technology trends and regulatory frameworks in the Global HPV Associated Disorders Market?

6. What is the market share of the leading vendors in the Global HPV Associated Disorders Market?

7. What modes and strategic moves are considered suitable for entering the Global HPV Associated Disorders Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. HPV Associated Disorders Market, by Indication, 2022 vs 2030
  • 4.3. HPV Associated Disorders Market, by Therapy, 2022 vs 2030
  • 4.4. HPV Associated Disorders Market, by Distribution, 2022 vs 2030
  • 4.5. HPV Associated Disorders Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of HPV related diseases
      • 5.1.1.2. Growth and development in targeted therapies
      • 5.1.1.3. Proactive government support and initiatives for HPV disorders awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects associated with HPV
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased funding and investment for cancer research
      • 5.1.3.2. Growing technological advancement in HPV co-testing
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of patient awareness regarding several treatments options
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. HPV Associated Disorders Market, by Indication

  • 6.1. Introduction
  • 6.2. AIN
  • 6.3. Anal Cancer
  • 6.4. Cervical Cancer
  • 6.5. CIN
  • 6.6. Genital Warts

7. HPV Associated Disorders Market, by Therapy

  • 7.1. Introduction
  • 7.2. Prevention
  • 7.3. Treatment

8. HPV Associated Disorders Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas HPV Associated Disorders Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific HPV Associated Disorders Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa HPV Associated Disorders Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

1. Alembic Pharmaceuticals

2. AstraZeneca plc

3. Bausch Health Companies Inc

4. Biocon Ltd.

5. Bristol-Myers Squibb Co.

6. Eli Lilly and Company.

7. F. Hoffmann-La Roche Ltd

8. GEA Group Aktiengesellschaft

9. GlaxoSmithKline plc

10. Inovio Pharmaceuticals, Inc.

11. J.M. Huber Corporation

12. Johnson & Johnson Services, Inc.

13. KinoPharma, Inc.

14. Merck & Co., Inc.

15. Novartis AG

16. Pfizer, Inc.